BI Asset Management Fondsmaeglerselskab A S Grows Stake in Revvity Inc. $RVTY

Key Points

• BI Asset Management Fondsmaeglerselskab A S increased its holdings in Revvity Inc. by 68.0%, owning 6,747 shares valued at $714,000 at the end of the first quarter.
• Revvity reported $1.18 EPS for the last quarter, exceeding analysts' expectations, with a revenue of $720.28 million.
• The company announced a quarterly dividend of $0.07 per share, to be paid on November 7th, with a yield of 0.3%.

BI Asset Management Fondsmaeglerselskab A S boosted its holdings in Revvity Inc. (NYSE:RVTY - Free Report) by 68.0% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,747 shares of the company's stock after acquiring an additional 2,731 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S's holdings in Revvity were worth $714,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in RVTY. Optiver Holding B.V. bought a new position in Revvity in the 4th quarter worth about $33,000. Quarry LP increased its position in shares of Revvity by 45.7% during the 4th quarter. Quarry LP now owns 303 shares of the company's stock valued at $34,000 after purchasing an additional 95 shares during the last quarter. Vermillion Wealth Management Inc. bought a new position in shares of Revvity during the 4th quarter valued at about $41,000. New Age Alpha Advisors LLC bought a new position in shares of Revvity during the 1st quarter valued at about $44,000. Finally, Continuum Advisory LLC increased its position in shares of Revvity by 39.3% during the 4th quarter. Continuum Advisory LLC now owns 471 shares of the company's stock valued at $53,000 after purchasing an additional 133 shares during the last quarter. 86.65% of the stock is currently owned by institutional investors.

Revvity Trading Down 0.4%

NYSE RVTY traded down $0.33 on Thursday, hitting $88.26. The company's stock had a trading volume of 198,797 shares, compared to its average volume of 1,177,646. Revvity Inc. has a 52-week low of $85.12 and a 52-week high of $129.50. The company has a current ratio of 3.33, a quick ratio of 2.75 and a debt-to-equity ratio of 0.43. The company's 50-day simple moving average is $94.31 and its 200 day simple moving average is $98.44. The firm has a market cap of $10.24 billion, a P/E ratio of 37.36, a PEG ratio of 2.45 and a beta of 0.91.

Revvity (NYSE:RVTY - Get Free Report) last released its quarterly earnings data on Monday, July 28th. The company reported $1.18 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.04. Revvity had a return on equity of 7.66% and a net margin of 10.19%.The business had revenue of $720.28 million during the quarter, compared to analysts' expectations of $711.26 million. During the same quarter last year, the business posted $1.22 EPS. The business's revenue was up 4.1% on a year-over-year basis. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. Research analysts predict that Revvity Inc. will post 4.94 EPS for the current fiscal year.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 17th will be issued a $0.07 dividend. The ex-dividend date is Friday, October 17th. This represents a $0.28 annualized dividend and a yield of 0.3%. Revvity's dividend payout ratio (DPR) is 11.86%.

Wall Street Analysts Forecast Growth

RVTY has been the topic of several recent research reports. Bank of America reduced their price objective on Revvity from $116.00 to $110.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. UBS Group upgraded Revvity from a "neutral" rating to a "buy" rating and reduced their price objective for the company from $145.00 to $115.00 in a research report on Thursday, May 1st. Wall Street Zen lowered Revvity from a "buy" rating to a "hold" rating in a research report on Sunday, August 3rd. Stifel Nicolaus reduced their price objective on Revvity from $120.00 to $110.00 and set a "hold" rating on the stock in a research report on Tuesday, July 29th. Finally, Raymond James Financial reiterated an "outperform" rating and set a $115.00 price objective (down from $120.00) on shares of Revvity in a research report on Tuesday, July 29th. Ten investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $120.07.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.